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Abstract:	Pyoderma	gangrenosum	(PG)	is	an	uncommon	neutrophilic	dermatosis,	with	variable	clinical	features,	nonspecific	
histopathology	and	multifactorial	pathogenesis,	posing	a	challenging	diagnosis	for	the	dermatologist.	Pyoderma	gangrenosum	
is a diagnosis of exclusion and should be included in the differential diagnoses of the  verrucous syndrome. We report  a 
granulomatous variant affecting the face. 
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Pyoderma	gangrenosum	(PG)	is	an	uncommon	entity	with	
a	diverse	clinical	spectrum	and	nonspecific	histopathology.	Aware-
ness	 of	 its	 various	manifestations,	 as	well	 as	 its	differential	 diag-
noses,	is	essential	for	early	therapy	to	reduce	morbidity.	On	initial	
approach,	PG	should	also	be	remembered	as	a	clinical	hypothesis	of	
the verrucous syndrome.
We report a 72-year-old male patient who sought care for 
painful facial lesions that had evolved over six months. He reported 
that	the	first	lesion	appeared	in	the	right	temporal	region	and	had	
rapidly	and	progressively	worsened.	Subsequently,	a	smaller	lesion,	
though	similar	to	the	first	one,	appeared	in	the	left	temporal	region.	
The	patient	was	a	 smoker	 (more	 than	30	pack-years	 ),	previously	
healthy,	and	denied	the	use	of	medications.
	 The	 lesions	 consisted	 of	 verrucous,	 ulcerated,	 crusted	
plaques	with	erythematoviolaceous	and	infiltrated	borders,	initial-
ly	in	the	right	temporomalar	region,	with	later	involvement	of	the	
contralateral	area	(Figure	1).	Two	KOH	preparations	yielded		blasto-
conidia	and	yeast-form	hyphae,	and	oral	itraconazole	therapy	insti-
tuted four months before showed no improvement. 
On	histopathology,	a	chronic	granulomatous	inflammatory	
process	(Figure	2),	with	negative	tests	for	fungi	(PAS	and	Grocott)	
and	mycobacteria	(Ziehl-Neelsen),	was	observed	.	The	samples	sent	
for	 detection	 and	 culturing	 of	 fungi,	 bacteria,	 and	 mycobacteria	
were negative. Direct inspection for Leishmania sp. (Giemsa) on the 
lesion was negative; the Mantoux	(PPD)	test	was	nonreactive.
After	 excluding	 infectious	 and	 neoplastic	 causes,	 the	 hy-
pothesis of granulomatous PG variant was discussed and estab-
lished	 as	 the	 principal	 possibility.	 Prednisone	 (1mg/kg/day),	 in	
combination	 with	 trimethoprim/sulfamethoxazole	 (TMP/SMX;	
800mg	+	160mg),	was	initiated,	with	regression	of	the	lesions	in	the	
first	 month	 of	 treatment.	 Prednisone	 was	 gradually	 tapered	 and	
dapsone		(50mg/day)	substituted	for	TMP/SMX.	Currently,	the	pa-
tient	 remains	asymptomatic	on	dapsone	 (100mg/day)	alone	 .	The	
investigation for underlying diseases possibly associated with PG 
showed no abnormalities.
PG,	first	described	by	Brocq1 and named by Brunsting et al.2 
in	1930,	is	a	rare	neutrophilic	dermatosis	of	unknown	etiology	clas-
sically	characterized	by	a	crusted	and	painful	ulcer	with	violaceous	
and undermined borders.3	The	clinical	spectrum	is	varied,	and	the	
diagnosis is based on clinicopathological correlation and on the ex-
clusion of other causes. 
PG	can	occur	at	any	age,	with	predominance	in	adult	wom-
en	between	the	second	and	fifth	decades	of	life.	Its	pathogenesis	is	
multifactorial	and	involves	neutrophilic	disfunction,	inflammatory	
Received 16 July 2017.
Accepted	13	October	2017.
*	 	Work	conducted	at	the	Ambulatório	de	Dermatologia	Sanitária	de	Porto	Alegre,		Porto	Alegre	(RS),	Brazil.
 Financial support: None.
	 Conflict	of	interests:	None.	
1	 Ambulatório	de	Dermatologia	Sanitária	de	Porto	Alegre,	Porto	Alegre	(RS),	Brazil.
2	 Service	of	Dermatology,		Hospital	de	Clínicas	de	Porto	Alegre,	Universidade	Federal	do	Rio	Grande	do	Sul,		Porto	Alegre	(RS),	Brazil.
Mailing address:
Kenselyn Oppermann
E-mail:	kenselyn@gmail.com	
©2018	by	Anais	Brasileiros	de	Dermatologia
An Bras Dermatol. 2018;93(4):605-7.
mediators and genetic predisposition. It has been described in as-
sociation	with	underlying	systemic	diseases	in	50%	of	cases,	most	
commonly	inflammatory	bowel	disease,	rheumatological	or	hema-
tological	 conditions	 (monoclonal	 gammopathy,	 myelodysplasia,	
acute	myeloid	leukemia).4 
Although	 the	 classic	 morphology	 comprises	 	 nodules	 or	
papules	 that	 evolve	 into	 rapidly	 progressive,	 painful	 ulcers	with	
violaceous	 borders	 and	 a	 purulent	 base,	 there	 are	 many	 clinical	
variants	such	as	 	ulcerative,	bullous,	pustular	and	granulomatous	
subtypes.5	Granulomatous	PG	can	exhibit	verrucous	characteristics,	
as in the present case.
The	histopathology	is	nonspecific	and	depends	on	the	sub-
type	of	the	lesion	and	on	the	duration	of	evolution,	but	it	contributes	
to	the	exclusion	of	other	diseases.	There	is	neutrophilic	infiltration	
in	recent	lesions,	and	necrosis	associated	with	fibrosis	in	the	chronic	
lesions,	as	well	as	a	granulomatous	process;	however,	these	findings	
are not pathognomonic.5 
The	diagnosis	 is	often	challenging	and	delayed,	 requiring	
clinical and pathological correlation; hence the importance of famil-
iarity with the differential diagnoses and morphological aspects. It 
should be noted that PG may be included as a differential diagnosis 
of	the	verrucous	syndrome,	classically	recognized	by	the	mnemon-
ic	 term	 “PLECT”	 (paracoccidioidomycosis,	 leishmaniasis,	 sporo-
trichosis,	chromomycosis,	tuberculosis).	Histoplasmosis	should	also	
be considered. 
Negative screening investigation for systemic  disease 
prompted us to consider the idiopathic nature of PG in our patient. 
Facial	involvement	was	striking	and	the		excellent	response	to	both	
steroid  and sulfonamide should be highlighted. Given the distinct 
verrucous aspect that granulomatous PG can present (which has 
long	been	described	in	the	literature),	could	a	second	“P”	be	added	
to	the	term	PLECT	(pyoderma-PLECT,	or	PPLECT)?		The	reminder	
of	this	clinical	form	of	PG	by	means	of	a	well-known	mnemonic	tool	
probably	results	in	greater	diagnostic	accuracy	in	difficult	cases	of	
the verrucous syndrome.
The most effective treatment for PG is systemic corticother-
apy,	which	 can	be	 administered	 through	pulse	 therapy	 for	 	more	
severe	 cases.	 Other	 medications	 with	 antineutrophilic	 potential,	
such	as	dapsone	and	other	sulfonamides,	and	clofazimine	can	also	
be	used,	as	 in	the	present	case.	Cyclosporin,	azathioprine,	and	in-
fliximab	have	also	been	employed	as	alternative	drugs	in	refractory	
cases.6 q
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FIgure 1: Before and after treatment. 
Left:	 extensive	 verrucous	 plaque	 in	
the	 right	 temporomalar	 region,	with	
erythematous	and	infiltrated	borders	
and	scaly,	crusted	central	ulcerations.	
Right: appearance after the estab-
lished therapy
FIgure 2: Histopathology:	 chronic	 granulomatous	 inflammatory	
process	(Hematoxylin	&	eosin,	x200)
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